Forastiere j clin oncol 1992

Author: zckl

August undefined, 2024

WebJun 4, 2024 · J Clin Oncol 1992;10:257-63. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil … WebApr 11, 2024 · TP53 mutations are less frequent in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) than in solid tumors, except in secondary and therapy-related MDS/AMLs, and in cases with complex monosomal karyotype. As in solid tumors, missense mutations predominate, with the same hotspot mutated codons (particularly codons 175, …

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk

WebApr 4, 2024 · A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck … WebBurtness, B.A.; Manola, J.; Axelrod, R.; Argiris, A.; Forastiere, A.A. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19 (5):977-983. careers through trade school

Preliminary results of Radiation Therapy Oncology Group 97-03: a ...

WebSep 1, 2007 · Purpose: Taxane-based concurrent chemoradiotherapy (CCR) for head and neck cancers has proven to have a favorable toxicity profile compared with cisplatin and radiation. This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and … WebForastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus … WebOct 4, 1992 · J Clin Oncol. 1992 Apr;10(4):647-56. doi: ... C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, et al. Affiliation 1 Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, Baltimore, MD 21205. brooklyn special effects beer review

Platinum-Based Chemotherapy plus Cetuximab in Head and …

Arlene A Forastiere, M.D., Professor of Oncology

WebCisplatin plus 5-fluorouracil (5-FU) (PF regimen) induction chemotherapy (IC) has been studied over the last two decades and has proven to be a durable and effective therapy for patients with locally advanced squamous cell cancer of the head and neck (SCCHN). Although randomized trials and meta-analyses have demonstrated that PF-based IC … WebSep 1, 2013 · A.A. Forastiere, B. Metch, D.E. Schuller, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study ... J Clin Oncol, 10 (1992), pp. 1245-1251. View Record in Scopus Google Scholar. 4. brooklyn space furnitureWebDec 5, 1994 · Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma J Clin Oncol. 1994 May;12(5):946-53.doi: 10.1200/JCO.1994.12.5.946. Authors S G Urba 1 , A A Forastiere, G T Wolf, R M Esclamado, P W McLaughlin, A F Thornton Affiliation brooklyn space co

"WebFeb 27, 2024 · J Clin Oncol 1992; 10:257. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15:283. ... J Clin Oncol 2004; 22:262. Forastiere AA, Leong T, Rowinsky E, et al. … " - Forastiere j clin oncol 1992

Forastiere j clin oncol 1992

Phase I and pharmacologic study of topotecan: a novel …

WebJul 1, 1994 · J Clin Oncol, 10 (1992), pp. 257-263. ... Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. WebApr 12, 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer.

Did you know?

WebSchantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. ... a Southwest Oncology Group study. J Clin Oncol 1992;10: ... WebJan 1, 2003 · Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P <.0001) and 77% enrolled in arm C (P <.001).

WebApr 1, 1992 · Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 01 Apr 1992, 10(4): 647-656 DOI: 10.1200/jco.1992.10.4.647 PMID: … WebApr 1, 1992 · A phase I and pharmacologic study was undertaken to determine the maximum-tolerated dose (MTD), describe the principal toxicities, and characterize the pharmacologic behavior of topotecan, which is a semisynthetic analog of camptothecin with broad preclinical antitumor activity and the first topoisomerase I-targeting agent to enter …

WebSep 8, 2015 · Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 08 Sep 2015, 33(29): 3262-3268 DOI: 10.1200/jco.2015.61.2978 PMID: 26351339 PMCID: PMC5320920. Review Free to read WebSummary. Francesco Forastiere, MD, Ph.D, is with the National Research Council (CNR) in Palermo, Italy and is visiting professor at Imperial College, London. He has served for 37 …

WebJournal of Clinical Oncology. 2003 Jan 1;21(1):92-98. doi: 10.1200/JCO.2003.01.008 Adelstein, David J. ; Li, Yi ; Adams, George L. et al. / An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer .

WebSep 9, 1991 · 1 Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, Baltimore, MD 21205. PMID: 1678780 DOI: 10.1200/JCO.1991.9.9.1692 Abstract Untreated and minimally pretreated solid tumor patients received alternating sequences of taxol and cisplatin. brooklyn special effects alcohol free beerWebAbstract. Introduction: Forestier's disease affects the spinal column of primarily elderly men. It is not rare, but it is often undiagnosed and can lead to significant morbidity and … career stint meaningWebJul 15, 2004 · J Clin Oncol. 2004 Jul 15;22(14 ... A S Garden 1 , J Harris, E E Vokes, A A Forastiere, J A Ridge, C Jones, E M Horwitz, B S Glisson, L Nabell, J S Cooper, W Demas, E Gore. Affiliation 1 Department of Radiation Oncology, Unit 97, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA ... brooklyn special effects amberWebThyroid gland is an uncommon site of metastasis, and metastasis to the gland secondary to nasopharyngeal carcinoma is seldom seen. We were only able to identify eight reported cases in the literature. A 61-year-old man, diagnosed case of careers titanWebApr 12, 2024 · Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. ... J Clin Oncol. 1992; 10(2):257-263. doi:10.1200/ JCO.1992.10.2.257 5. Vermorken JB, … brooklyn space heaterWebInt J Radiat Oncol Biol Phys 1992;23: 706-713. Crossref; Web of Science; Google Scholar. 5. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors ... careers the next generation foundationWebBurtness, B.A.; Manola, J.; Axelrod, R.; Argiris, A.; Forastiere, A.A. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent … careers tik tok